

Featured data at EADV 2025

Johnson&Johnson

European Academy of Dermatology and Venereology

Paris, France
September 17-21, 2025

Johnson & Johnson Sponsored Studies		
Poster/ Presentation Number	Title	Presentation time (CET)
Icotrokinra | PsO | ICONIC LEAD Study		
Late Breaking Oral Presentation		
D1T01.2B	Maintenance of Response with Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Psoriasis: Randomized Treatment Withdrawal in Adults (Weeks 24-52) and Continuous Treatment in Adolescents (Through Week 52) From the Phase 3, ICONIC-LEAD Trial	Wednesday, September 17 16:15-16:30
Oral Presentation		
FCO2.1H*	Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)*	Thursday, September 18 11:25-11:35
ePosters		
P2808	Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study	N/A
P3252	High-Level Improvements in Psoriasis Area and Severity Index With Icotrokinra in Participants With Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3 ICONIC-LEAD Study	N/A

Icotrokinra | PsO | ICONIC ADVANCE 1 and 2 Studies		
Oral Presentation		
FC01.1G	Icotrokinra Demonstrated Superior Responses Compared With Placebo and Deucravacitinib in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3 ICONIC-ADVANCE 1&2 Studies	Thursday, September 18 9:30-9:40

Icotrokinra | PsO | FRONTIER Study		
ePoster		
P2560*	Icotrokinra, a Novel Targeted Oral Peptide, in Patients with Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis*	N/A

TREMFYA® (guselkumab) | PsA | APEX Study		
	ePoster	
P3437*	Inhibition of Structural Damage Progression With the Selective IL-23i Guselkumab in Participants With Active PsA: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled APEX Study*	N/A

TREMFYA® (guselkumab) | PsO | GUIDE Study		
	Oral Presentations	
FC01.1B	Exploring Super Responders Who Remained Treatment-Free for More Than 3 Years After Guselkumab Withdrawal: Insights From the Phase 3b GUIDE Trial in Psoriasis	Thursday, September 18 8:40-8:50
FC02.1F	Early Intervention With Guselkumab is Associated With Greater Efficacy and Higher Rates of Complete Skin Clearance Independent of Super Responder Status: The Phase 3b GUIDE Trial in Psoriasis	Thursday, September 18 11:05-11:15
	ePoster	
P2645	GUIDE Phase 3b Trial Results: Early Intervention With Guselkumab Results in Higher Rates of Fingernail Psoriasis Clearance and Maintenance of Nail Response Following Treatment Withdrawal*	N/A

TREMFYA® (guselkumab) | PsO | VISIBLE Study		
	Oral Presentation	
FC02.1G*	VISIBLE: Guselkumab Impact on Psoriatic Arthritis Through Week 48 in Participants With Moderate-to-Severe Psoriasis Across All Skin Tones*	Thursday, September 18 11:15-11:25
	ePosters	
P3364*	VISIBLE Cohort A: Guselkumab Demonstrated Skin Clearance and Improved Health-Related Quality of Life Through Week 48 in Participants with Moderate-to-Severe Plaque Psoriasis Across All Skin Tones*	N/A
P2199*	VISIBLE Cohort B: Guselkumab Demonstrated Scalp Clearance and Improved Health-Related Quality of Life Through Week 48 in Participants with Moderate-to-Severe Scalp Psoriasis Across All Skin Tones*	N/A

*Encore abstract

TREMFYA® (guselkumab) | PsA | PsABIOnd Study		
Short Oral Presentation		
EPS04.1	Patient Reported Impact and Satisfaction With Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: 12-month Results of the PsABIOnd Observational Study	Wednesday September 17 17:03-17:10
ePoster		
P3828	Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 12-month Results of the PsABIOnd Observational Study	N/A

TREMFYA® (guselkumab) | PsO | SPECTRUM Study		
ePosters		
P3886*	SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement*	N/A
P3388*	SPECTREM: Guselkumab Efficacy Across Multiple High-Impact Sites in Participants With Low BSA Moderate Plaque Psoriasis*	N/A

TREMFYA® (guselkumab) | Pediatric PsO | PROTOSTAR Study		
ePoster		
P1867*	Guselkumab Pharmacokinetics and Immunogenicity in Pediatric Psoriasis: Phase 3 PROTOSTAR Study*	N/A

TREMFYA® (guselkumab) | PsO | China Studies		
ePosters		
P2219	Super-Response to Guselkumab Treatment in Chinese Patients With Moderate-to-Severe Psoriasis: a Post-Hoc Analysis From a Phase 4 RCT	N/A
P2165	Efficacy of Guselkumab Through 48 Weeks in Chinese Psoriasis Patients With and Without Metabolic Comorbidities: a Post-Hoc Analysis of a Phase 4 RCT	N/A
P2163	Maintenance of Response After Guselkumab Withdrawal: Findings From an Observational Study in Chinese Patients With Moderate-to-Severe Plaque Psoriasis	N/A
P2164	Predictors of Psoriasis Relapse After Guselkumab Withdrawal: An Observational Analysis of Chinese Patients	N/A

*Encore abstract

TREMFYA® (guselkumab) | PsO | Real World Evidence Studies		
	ePosters	
P2070	**G-REAL:** Guselkumab Shows Strong Long-Term Effectiveness and High Drug Survival in Patients With Moderate-to-Severe Psoriasis Across Different Treatment Lines – First Interim Results of the Non-Interventional German G-REAL Study	N/A
P2137	**RECAP:** Real-World Characteristics of Patients Initiating Advanced Therapy for Plaque Psoriasis in the US Specialty Dermatology Networks	N/A
P3695	**CASSIOPEE:** Impact of Guselkumab in Real-Life on Sleep Quality Measured Using a Wearable Device in Patients With Moderate to Severe Psoriasis: Data From the CASSIOPÉE Study	N/A
P3146	**GAIA:** Persistence of Guselkumab in Psoriatic Disease Over 3 Years in Real Life Conditions, a Nationwide Claims Database Analysis	N/A
P2175*	**CERES**: Baseline Characteristics of Patients With Moderate-to-Severe Plaque Psoriasis Treated With Guselkumab Self-Administered Using the One-Press Injector in Portugal: A Study on Treatment Satisfaction*	N/A

PsO | Other Real World Evidence Studies		
ePosters		
P2807	Treatment of Moderate-to-Severe Psoriasis With First-Line Tumor Necrosis Factor Inhibitors or Apremilast is Associated With Fast and Frequent Treatment Failures and Greater Healthcare Resource Utilization and Costs	N/A
P2154	Achieving Clear or Almost-Clear Skin Clearance in Moderate-to-Severe Psoriasis is Associated With Clinically Meaningful Itch Reduction and Lower Healthcare Costs	N/A
P2148	Exploring the Value of Achieving Complete or Near Complete Skin Clearance in Patients With a History of Moderate-Severe Psoriasis: A Real-World Survey in Europe	N/A

*Encore abstract

TREMFYA® IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TREMFYA®?

TREMFYA® is a prescription medicine that may cause serious side effects, including:

- **Serious Allergic Reactions.** Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
  - fainting, dizziness, feeling lightheaded (low blood pressure)
  - swelling of your face, eyelids, lips, mouth, tongue or throat
  - trouble breathing or throat tightness
  - chest tightness
  - skin rash, hives
  - itching

- **Infections.** TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- blood in your phlegm (mucus)
- burning when you urinate or urinating more often than normal

Do not use TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®.

Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “What is the most important information I should know about TREMFYA®?”
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®.

- are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

What are the possible side effects of TREMFYA®?

TREMFYA® may cause serious side effects. See "What is the most important information I should know about TREMFYA®?"

The most common side effects of TREMFYA® include: upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections and bronchitis.

These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects.

Use TREMFYA® exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information, including Medication Guide for TREMFYA®, and discuss any questions that you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Dosage Forms and Strengths: TREMFYA® is available in a 100 mg/mL prefilled syringe and One-Press patient-controlled injector for subcutaneous injection, a 200 mg/2 mL prefilled syringe and prefilled pen (TREMFYA® PEN) for subcutaneous injection, and a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.